Nasdaq Regulation



Eun Ah Choi Senior Vice President Global Head of Regulatory Operations

February 14, 2024

Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

Division of Corporation Finance:

This is to certify that on February 14, 2024, The Nasdaq Stock Market LLC (the "Exchange") received from Tevogen Bio Holdings Inc. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following securities:

> Common Stock, par value \$0.0001 per share Warrants, each exercisable for one share of Common Stock for \$11.50 per share

We further certify that the security described above has been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

En the Chri